AN2 Therapeutics (ANTX) Other Accumulated Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Other Accumulated Expenses data on file, last reported at $567000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 829.51% year-over-year to $567000.0 in Q1 2026; TTM through Mar 2026 was $567000.0, a 829.51% increase from a year earlier, with the FY2025 full-year figure at $50000.0, down 1.96% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $567000.0, up from $50000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for ANTX reached as high as $1.3 million in Q3 2024 and fell as low as $9000.0 in Q2 2022.
• Historically, Other Accumulated Expenses has averaged $315333.3 across 5 years, with a median of $61000.0 in 2025.
• On a YoY basis, Other Accumulated Expenses climbed as much as 1529.55% in 2025 and fell as far as 97.41% in 2025.
• Year by year, Other Accumulated Expenses stood at $122000.0 in 2022, then surged by 445.9% to $666000.0 in 2023, then slumped by 92.34% to $51000.0 in 2024, then fell by 1.96% to $50000.0 in 2025, then jumped by 1034.0% to $567000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $567000.0 in Q1 2026, $50000.0 in Q4 2025, and $33000.0 in Q3 2025.